Stc.unm

Other

University of Minnesota

Sandia Corporation

National Technology & Engineering Solutions of Sandia, LLC

University of Kansas-ku Medical Center Research Institute

University of New Mexico

Unm Rainforest Innovations

Sandia National Laboratories

Science & Technology Corporation &commat; Unm

Science & Technology Corporation & Unm

Senior Scientific LLC

Richard Smith Larson

Jeffrey P Norenberg

David R Wheeler

Darren W Branch

Thayne L Edwards

Edward R Flynn

David C Brown

Susan M Brozik

Brian Hjelle

Marco Bisoffi

Pam R Hall

Larry A Sklar

Jeffrey Aube

Bruce S Edwards

Jennifer Elizabeth Golden

Carston R Wagner

Warren S Weiner

Chad Schroeder

Tuanli Yao

Juan Jacob Strouse

Irena Ivnitski-Steele

Hadya M Khawaja

Jerec Warren Ricci

Viruses and other bioagents are of high medical and biodefense concern and their detection at concentrations well below the threshold necessary to cause health hazards continues to be a challenge with respect to sensitivity, specificity, and selectivity. Ideally, assays for accurate and real time detection of viral agents and other bioagents would not necessitate any pre-processing of the analyte, which would make them applicable for example to bodily fluids (blood, sputum) and man-made as well as naturally occurring bodies of water (pools, rivers). We describe herein a robust biosensor that combines the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents. In preferred embodiments, a lithium tantalate based SAW transducer with silicon dioxide waveguide sensor platform featuring three test and one reference delay lines was used to adsorb antibodies directed against Coxsackie virus B4 or the negative-stranded category A bioagent Sin Nombre virus (SNV), a member of the genus Hantavirus, family Bunyaviridae, negative-stranded RNA viruses. Rapid detection (within seconds) of increasing concentrations of viral particles was linear over a range of order of magnitude for both viruses, although the sensor was approximately 50&#xd7;10-fold more sensitive for the detection of SNV. For both pathogens, the sensor's selectivity for its target was not compromised by the presence of confounding Herpes Simplex virus type 1. The biosensor was able to detect SNV at doses lower than the load of virus typically found in a human patient suffering from hantavirus cardiopulmonary syndrome (HCPS). Further, in a proof-of-principle real world application, the SAW biosensor was capable of selectively detecting SNV agents in complex solutions, such as naturally occurring bodies of water (river, sewage effluent) without analyte pre-processing.

Detection of bioagents using a shear horizontal surface acoustic wave biosensor

The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma

The present invention provides pyrazolo[1,5-a]pyrimidine compounds which inhibit cancer-associated transporter proteins, methods of treating or preventing the onset of a cancer-associated transporter protein-mediated disease by administering such compounds, and pharmaceutical compositions comprising such compounds. In one embodiment, the invention provides pyrazolo[1,5-a]pyrimidine efflux inhibitors that are selective toward ABCG2 over ABCB1. Compounds and compositions according to the present invention may be used to treat cancer, including drug resistant (DR) and multiple drug resistant (MDR) cancers.

Selective efflux inhibitors and related pharmaceutical compositions and methods of treatment

An apparatus and method for performing biopsies in-vivo using magnetically labeled nanoparticles is disclosed. One embodiment of the apparatus is called a magnetic needle. When used in a biopsy, one embodiment of the present invention collects diseased cells in-vivo which have been tagged with magnetic nanoparticles coated with receptors for specific diseased cells.

Magnetic needle biopsy

A biosensor combining the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents. In a preferred embodiment, a lithium tantalate based SAW transducer with silicon dioxide waveguide sensor platform featuring three test and one reference delay lines was used to adsorb antibodies directed against Coxsackie virus B4 or the negative-stranded category A bioagent Sin Nombre virus (SNV). Rapid detection of increasing concentrations of viral particles was linear over a range of order of magnitude for both viruses, and the sensor's selectivity for its target was not compromised by the presence of confounding Herpes Simplex virus type 1 The biosensor was able to delect SNV at doses lower than the load of virus typically found in a human patient suffering from hantavirus cardiopulmonary syndrome (HCPS).

An apparatus and method for performing biopsies in-vivo using magnetically labeled nanoparticles is disclosed. One embodiment of the apparatus is called a magnetic needle. When used in a biopsy, one embodiment of the present invention collects cancer cells in-vivo which have been tagged with magnetic nanoparticles coated with antibodies for specific cancer or tumor cells.

The present invention provides a compound and a method of making a compound according to the following formula:where Ris an alkyl group having 1 to 12 carbons; Ris a urea group; Ris an active group, such as fluorescein, a toxin, radiolabel or drug; and R, Rand Rare each independently a halide group.

Small molecules for inhibition of function and drug delivery to leukocytes

Cyclic peptides inhibit LFA-1 interaction with ICAM-1 and are useful in treatment of hematopoietic neoplasms and in adjunct therapy in prevention of retinoic acid syndrome and diseases involving emigration of leukocytes into organ tissue.

Peptide inhibitors of LFA-1/ICAM-1 interaction

Growing community of inventors

Albuquerque, NM, United States of America

Richard Smith Larson